Crosby, E., Nagata, H., Telli, M., Acharya, C., Wapnir, I., Zablotsky, K., … Lyerly, H. (2020). 789 Intratumoral plasmid IL-12 expands CD8+ T cells and induces a clinically validated CXCR3 signature in triple-negative breast cancer. In Late-breaking abstracts (pp. A838–A838). BMJ Publishing Group Ltd. https://doi.org/10.1136/jitc-2020-sitc2020.0789

Crosby, Erika, Hiroshi Nagata, Melinda Telli, Chaitanya Acharya, Irene Wapnir, Kaitlin Zablotsky, Erica Browning, et al. “789 Intratumoral plasmid IL-12 expands CD8+ T cells and induces a clinically validated CXCR3 signature in triple-negative breast cancer.” In Late-Breaking Abstracts, A838–A838. BMJ Publishing Group Ltd, 2020. https://doi.org/10.1136/jitc-2020-sitc2020.0789.

Crosby E, Nagata H, Telli M, Acharya C, Wapnir I, Zablotsky K, et al. 789 Intratumoral plasmid IL-12 expands CD8+ T cells and induces a clinically validated CXCR3 signature in triple-negative breast cancer. In: Late-breaking abstracts. BMJ Publishing Group Ltd; 2020. p. A838–A838.

Crosby, Erika, et al. “789 Intratumoral plasmid IL-12 expands CD8+ T cells and induces a clinically validated CXCR3 signature in triple-negative breast cancer.” Late-Breaking Abstracts, BMJ Publishing Group Ltd, 2020, pp. A838–A838. Crossref, doi:10.1136/jitc-2020-sitc2020.0789.

Crosby E, Nagata H, Telli M, Acharya C, Wapnir I, Zablotsky K, Browning E, Hermiz R, Svenson L, Bannavong D, Malloy K, Canton D, Twitty C, Osada T, Lyerly H. 789 Intratumoral plasmid IL-12 expands CD8+ T cells and induces a clinically validated CXCR3 signature in triple-negative breast cancer. Late-breaking abstracts. BMJ Publishing Group Ltd; 2020. p. A838–A838.